C. Elizabeth Parsons, Raoul Nelson, Linda S. Book, M. Kyle Jensen – 1 September 2014 – Limited data on short‐ and long‐term outcomes of renal replacement therapy (RRT) in pediatric liver transplantation (LT) patients exist. We evaluated risk factors for RRT in pediatric LT recipients with hepatorenal syndrome (HRS) and described the outcomes. We performed a single‐center, case‐control study of LT recipients who required RRT for HRS from 1999 to 2011. Three controls who did not receive RRT were matched with each case on the basis of age, diagnosis, and LT date.

Jan M. Knaak, Vinzent N. Spetzler, Nicolas Goldaracena, Markus U. Boehnert, Fateh Bazerbachi, Kristine S. Louis, Oyedele A. Adeyi, Leonid Minkovich, Paul M. Yip, Shaf Keshavjee, Gary A. Levy, David R. Grant, Nazia Selzner, Markus Selzner – 1 September 2014 – An ischemic‐type biliary stricture (ITBS) is a common feature after liver transplantation using donation after cardiac death (DCD) grafts.

Dominique Thabut, Marika Rudler, Nina Dib, Nicolas Carbonell, Philippe Mathurin, Faouzi Saliba, Alain Mallet, Julien Massard, Brigitte Bernard‐Chabert, Frederic Oberti, Paul Cales, Jean‐Louis Golmard, Christophe Bureau, for the French Club for the Study of Portal Hypertension (CFEHTP) – 1 September 2014 – The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials.

Deepak Joshi, George J. Webster – 1 September 2014

Amy S. Lee, Wan‐Ting Chen – 30 August 2014

Fu‐Sheng Wang, Jian‐Gao Fan, Zheng Zhang, Bin Gao, Hong‐Yang Wang – 28 August 2014 – Liver disease is a major cause of illness and death worldwide. In China alone, liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]), nonalcoholic fatty liver disease, and alcoholic liver disease, affect approximately 300 million people.

Fu‐Sheng Wang, Jian‐Gao Fan, Zheng Zhang, Bin Gao, Hong‐Yang Wang – 28 August 2014 – Liver disease is a major cause of illness and death worldwide. In China alone, liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]), nonalcoholic fatty liver disease, and alcoholic liver disease, affect approximately 300 million people.

Saleh Rachidi, Shaoli Sun, Zihai Li – 28 August 2014

Fu‐Sheng Wang, Jian‐Gao Fan, Zheng Zhang, Bin Gao, Hong‐Yang Wang – 28 August 2014 – Liver disease is a major cause of illness and death worldwide. In China alone, liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]), nonalcoholic fatty liver disease, and alcoholic liver disease, affect approximately 300 million people.

Margaret Hellard, David A Rolls, Rachel Sacks‐Davis, Garry Robins, Philippa Pattison, Peter Higgs, Campbell Aitken, Emma McBryde – 28 August 2014 – With the development of new highly efficacious direct‐acting antiviral (DAA) treatments for hepatitis C virus (HCV), the concept of treatment as prevention is gaining credence. To date, the majority of mathematical models assume perfect mixing, with injectors having equal contact with all other injectors. This article explores how using a networks‐based approach to treat people who inject drugs (PWID) with DAAs affects HCV prevalence.